What is the equity of Mesoblast this year?
Mesoblast has equity of 480.36 M USD this year.
Mesoblast Equity 2025
Mesoblast Equity
480.36 M USD
Ticker
MSB.AX
ISIN
AU000000MSB8
WKN
A0DNPW
In 2025, Mesoblast's equity was 480.36 M USD, a -4.28% increase from the 501.84 M USD equity in the previous year.
Mesoblast Aktienanalyse
What does Mesoblast do?
Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Mesoblast's Equity
Mesoblast's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mesoblast's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Mesoblast's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Mesoblast's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Mesoblast’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Mesoblast stock
What was the equity of Mesoblast compared to the previous year?
The equity of Mesoblast has increased/decreased by -4.28% decreased compared to the previous year.
What impact does a high equity have on investors of Mesoblast?
A high equity is advantageous for investors of Mesoblast as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Mesoblast?
A low equity can be a risk for investors of Mesoblast, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Mesoblast affect the company?
An increase in equity of Mesoblast can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Mesoblast affect the company?
A reduction in equity of Mesoblast can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Mesoblast?
Some factors that can affect the equity of Mesoblast include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Mesoblast so important for investors?
The equity of Mesoblast is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Mesoblast take to change the equity?
To change equity, Mesoblast can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Mesoblast pay?
Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.
What is the dividend yield of Mesoblast?
The current dividend yield of Mesoblast is .
When does Mesoblast pay dividends?
Mesoblast pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mesoblast?
Mesoblast paid dividends every year for the past 0 years.
What is the dividend of Mesoblast?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mesoblast located?
Mesoblast is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mesoblast from 7/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/20/2025.
When did Mesoblast pay the last dividend?
The last dividend was paid out on 7/20/2025.
What was the dividend of Mesoblast in the year 2024?
In the year 2024, Mesoblast distributed 0 USD as dividends.
In which currency does Mesoblast pay out the dividend?
The dividends of Mesoblast are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mesoblast
Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
